![]() ![]() Traditional measures of CBV were not predictive of PFS or OS. An atlas-defined hypervascular tumor blood volume greater than 2.35 cc prior to treatment, 0.14 cc after treatment, and a decrease in atlas-defined hypervascular tumor volume less than 80% following treatment were characteristic of a shorter PFS and OS. Voxel-wise comparison of individual patient CBV maps to the atlas allowed delineation of elevated tumor perfusion from artery and normal cortical tissue. The volume of tumor tissue with elevated CBV, percentage of enhancing tumor with elevated CBV, and the mean and maximum change in normalized CBV intensity relative to the atlas were computed. MRI and CBV maps from 32 recurrent glioblastoma patients were then obtained prior to and following treatment with bevacizumab, registered to and compared with the CBV atlas. A CBV atlas was created by calculating the voxel-wise mean and variability in CBV. Z-score normalized CBV maps were registered to stereotactic atlas space in 450 patients with brain tumors. In the current study, we have constructed a large-scale radiographic atlas of CBV to assess treatment response to bevacizumab in individual patients with recurrent glioblastoma. Learn more about brain cancer care at UConn Health.Dynamic susceptibility contrast (DSC)-MRI is a well-established perfusion MR imaging technique for estimating relative cerebral blood volume (CBV) in primary brain tumors however, tumors localized to regions with naturally elevated perfusion, including cortical tissue and common vascular territories, make evaluation of tumor vascularity difficult to assess. UConn Health will share additional details about the research, including information on eligibility requirements and how patients can participate, later this year. “UConn Health’s involvement in this very promising trial affirms our standing as a world-class institution for clinical care and research in neuro-oncology.” Ketan Bulsara, chief of UConn Health’s Division of Neurosurgery. Becker’s leadership, and it is also a tribute to the great multidisciplinary team that has been created through the Carole and Ray Neag Comprehensive Cancer Center and our Brain and Spine Institute,” says Dr. ![]() “To be selected as one of a handful of sites in the world for this trial is truly a tribute to Dr. The investigators believe the one-two punch of therapies may be able to generate “a potent and specific anti-tumor response” in patients with recurrent malignant glioblastoma, a type of aggressive and often fatal brain tumor. LUMINOS-101 is how Istari Oncology is branding this clinical trial. (Images provided by Istari Oncology, Inc.) The therapy used, known as PVSRIPO, is being studied in combination with the cancer immunotherapy pembrolizumab, with UConn Health among a select few sites for this phase of the clinical trial. This is truly a landmark trial for patients with recurrent glioblastomas.” Comparative brain scans show the difference in tumor size from before infusion to 25 months after infusion. “We are extremely honored to be one of only a few selected sites for the LUMINOS-101 trial. Kevin Becker, director of neuro-oncology and UConn Health’s primary investigator for this trial. “This is a tremendous example of the innovative trials we envision as we build our neuro-oncology program at UConn,” says Dr. Istari Oncology, Inc., the North Carolina-based biotechnology company sponsoring the research, has selected UConn Health as a site for this phase of the trial. It is also being studied across a range of cancers including melanoma, for which the FDA has granted “orphan drug status.” ![]() Food and Drug Administration for recurrent glioblastoma. PVSRIPO has been granted “breakthrough therapy designation” from the U.S. The rationale for studying these agents in combination is evidence that indicates these drugs work synergistically to activate the immune system to fight cancer. The therapy combines what researchers are calling PVSRIPO, a viral immunotherapy based on the polio vaccine, with pembrolizumab, an immunotherapy drug shown to be effective in treating many other types of cancers, marketed under the brand name Keytruda. ‘This is a tremendous example of the innovative trials we envision as we build our neuro-oncology program at UConn.’ -Dr. As a promising new therapy for certain brain tumors reaches the second phase of clinical trials, UConn Health will be one of the select few locations in the United States to make this treatment available to patients during the further evaluation of its safety and efficacy. ![]()
0 Comments
Leave a Reply. |